A New Breakthrough in Targeted Treatment
Researchers at the Institute of Nano Science and Technology (INST) Mohali, under the Department of Science and Technology (DST), have pioneered a “self-actuating” drug delivery system that directly targets joint inflammation. This approach not only minimizes systemic side effects but also reduces dosing frequency, signaling a major leap forward in Rheumatoid Arthritis (RA) therapy.
How It Works
Using polymer-lipid hybrid micro-composites loaded with methotrexate, the system senses elevated levels of Matrix metalloproteinases (MMPs) in inflamed joints, then releases the encapsulated drug on demand. By responding to the precise biochemical signals of RA flare-ups, the formulation maximizes drug efficacy while minimizing adverse effects.
"These microspheres are engineered to sense inflammation in joints and release the drug only when needed, minimising side effects and improving therapeutic outcomes," INST Team.
Clinical Relevance for Physicians
Animal studies have shown significant reductions in joint swelling, inflammation, and cartilage damage, coupled with enhanced joint repair. For clinicians, this means potential for better patient compliance, fewer injections, and more controlled disease management.
Published in Biomaterial Advances, the research also hints at future applications in other inflammatory conditions, including synovitis and inflammatory bowel disease.
This innovative approach could reshape how rheumatologists and other specialists treat RA, offering a targeted, safer, and more effective alternative to conventional systemic therapies.
